Form 4: STERIS plc: CEO Daniel Carestio Acquires Shares and Stock Options
SEC Form 4
STERIS plc's CEO, Daniel A. Carestio, reports acquisition of shares and stock options.
Summary
- On June 4, 2024, Daniel A. Carestio, the President and CEO of STERIS plc, acquired 12,849 ordinary shares.
- Following this transaction, Carestio directly owns 56,316 ordinary shares.
- Carestio also acquired an option to buy 81,544 ordinary shares at a price of $251.34, exercisable in installments between June 4, 2025, and June 5, 2028.
- 28,295 of the ordinary shares are restricted and will lapse at various dates between October 1, 2024, and June 4, 2027.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's increased stake in the company could be seen as a positive signal, but it's a routine disclosure.
Positives
- The CEO's acquisition of shares and stock options could be interpreted as a positive signal, indicating confidence in the company's future performance.
Industry Context
This filing is a routine disclosure related to insider trading activities, which are common in publicly traded companies. It provides transparency regarding the transactions of company executives.
Comparison to Industry Standards
- Executive compensation packages often include stock options to align management's interests with those of shareholders.
- The vesting schedules for the restricted shares and stock options are typical for executive compensation plans.
- Comparing the size of the option grant and share ownership to peers in the medical equipment and supplies industry would provide further context.
Stakeholder Impact
- Shareholders may view the CEO's increased ownership as a positive sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/04/2024 | Date of transaction: Acquisition of shares and stock options. |
| 10/01/2024 | 289 restricted ordinary shares lapse. |
| 06/02/2025 | 4,308 restricted ordinary shares lapse. |
| 06/02/2025 | 1,514 restricted ordinary shares lapse. |
| 06/02/2025 | 2,369 restricted ordinary shares lapse. |
| 06/04/2025 | 4,283 restricted ordinary shares lapse. |
| 06/04/2025 | 20,386 stock options become exercisable. |
| 10/01/2025 | 289 restricted ordinary shares lapse. |
| 06/01/2026 | 4,308 restricted ordinary shares lapse. |
| 06/02/2026 | 2,369 restricted ordinary shares lapse. |
| 06/04/2026 | 4,283 restricted ordinary shares lapse. |
| 06/04/2026 | 20,386 stock options become exercisable. |
| 06/04/2027 | 4,283 restricted ordinary shares lapse. |
| 06/04/2027 | 20,386 stock options become exercisable. |
| 06/05/2028 | 20,386 stock options become exercisable. |
| 06/04/2034 | Expiration date for the acquired employee stock options. |
| 06/06/2024 | Date of signature for the report. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.